A
LZHEIMER DISEASE (AD) IS characterized by amyloid deposits and neurofibrillary degenerations. Almost 35% of AD cases have Lewy bodies and Lewy neurites, 1 resulting from the aggregation of ␣-synuclein, and most cases of dementia with Lewy bodies (DLB) have some AD changes. 2 Studies in transgenic mouse models for AD have shown that immunization with synthetic, preaggregated ␤-amyloid (A␤) has reduced the extent and progression of AD pathological features and has prevented the cognitive decline in these animals. 3, 4 An international multicenter, double-blind phase 2 study of active immunization with A␤ 42 (AN-1792) combined with the adjuvant QS-21 in mild to moderate AD was initiated in 2001 and discontinued after meningoencephalitis was reported. 5 Neuropathological examination of 3 immunized patients showed evidence of partial clearance of amyloid plaques and inflammatory changes. [6] [7] [8] We report the clinicopathological observation of a patient with AD treated with AN-1792(QS-21), who subsequently developed clinical evidence of DLB.
REPORT OF A CASE
A 74-year-old patient with a history of hypertension complained of progressive episodic memory disturbance for 3 years. The Mini-Mental State Examination score was 19 of 30, the Mattis Dementia Rating Scale score was 102 of 144, and the digit span was 5 forward and 2 in reverse order. The selective reminding test showed a severe impairment in all the memory processes. She had impairment in calculation, gestural and constructional praxis, gnosis, and judgment. She presented with word-finding difficulty and semantic paraphasic errors. Parkinsonism, hallucination, sleep disorder, and fluctuations were absent. The clinical features were consistent with the diagnosis of probable AD. 9 Her apolipoprotein genotype was E3/E3. She was treated with rivastigmine tartrate. Fourteen months later, the Mini-Mental State Examination score was 15 of 30. She was enrolled in the AN-1792 trial and received 2 injections of 225 µg of AN-1792 (Wyeth Research, Collegeville, Pa) plus 50 µg of QS-21 (Elan Pharmaceuticals, San Francisco, Calif) at an interval of 4 weeks (institutional review board approval from Comité Consultatifs de Protection des Personnes se prêtant à des Recherches Biomédicales, ParisCochin, France, July 23, 2001). The patient was considered an antibody responder to immunization with an IgG anti-AN-1792 antibody titer exceeding 10 000 (threshold, 1/2200) and an IgM titer exceeding 3500. Maximum serum anti-A␤ titers were reached in 4.7 months. Six months after the first injection, she presented with a fever of 38°C and headache. Although she always refused the lumbar puncture, encephalitis was rejected because of the absence of neurological modification and white matter changes on MRI. In the next months, she developed marked visual hallucinations, somniloquy, dreams, and disorientation on waking. The neurological examination revealed gait instability, righthand resting tremor, and hypertonia. During the 32 following months after immunization, the Mini-Mental State Examination score remained globally stable, despite fluctuations and several confusional episodes with pneumonia or diarrhea (Figure 1) , whereas the Lewy body features became more obvious. She lived at home with a professional caregiver after her husband's death, which she assumed adequately. She remained stable for cognitive functioning and instrumental activities of daily living. The patient died 34 months postimmunization, after an acute abdominal syndrome not related to the brain disease. The abdominal examination revealed numerous liver metastases of an adenocarcinoma.
Autopsy was performed 9 hours post mortem. The brain weighted 920 g (including the cerebellum). The hippocampus was more severely atrophied than the hemispheres. The right hemisphere was frozen and the left hemisphere was fixed in formalin for 6 weeks. The neuropathological examination was established according to consensus recommendations. 1, 10 The amyloid and tau pathological features were semiquantified by immunohistochemical and Western blot analyses as already described. 11 Synucleopathy was semiquantified by immunohistochemical analysis using the antibody 3B5 (Innogenetics, Gent, Belgium) and Western blot analysis. 2 Age-matched controls were 1 patient with AD (apolipoprotein genotype, E3/E4) and 1 woman devoid of any neurological disease (apolipoprotein genotype, E3/E4).
RESULTS
Neither focal amyloid deposit nor amyloid angiopathy was shown on Congo red and thioflavine stains. ␤-Amyloid immunolabeling did not disclose focal or diffuse deposit using 4 different anti-A␤ antibodies (ie, 3D6, 4G8, 6E10, and 6F3D) (Figure 2A and B) . The Gallyas technique showed in the hippocampus and temporal cortex clusters of neuritic processes reminiscent of senile plaques but devoid of amyloid core ( Figure 2C ) that were tau immunoreactive ( Figure 2D ). Tau-immunoreactive neurofibrillary tangles and neuropil threads were labeled in the entorhinal cortex, hippocampus, limbic cortices, and, to a lesser extent, the prefrontal lobe, reaching the final score of IV/VI according to the Braak stage 10 and 9c/10 according to the Western blot analysis. 12 Hematoxylin-eosin staining and ␣-synuclein labeling showed many Lewy bodies in the brainstem and limbic and neocortical regions, with a semiquantitative score of 4 (very severe) ( Figure 2E and F). 1 There was neither inflammation nor metastatic dissemination. No microglial activation was detected by anti-CD68 (macrophage labeling), anti-CR3/43 (HLA-DP, HLA-DQ, HLA-DR), and tomatolectin at light microscopy examination. Moreover, the burden of CR3/ 43-positive cells was lower in the brain of the patient compared with the control with AD. All neuropathological data were confirmed by Western blot analysis of frozen tissue (Figure 3) .
COMMENT
This study showed that A␤ immunization in a patient with a Lewy body variant of AD resulted in the total absence of A␤ plaques or angiopathy despite clear signs of AD, namely, Braak stage IV neurofibrillary tangle pathological features and apparent "ghost plaques" with neuritic change without amyloid cores in the absence of lymphocyte or macrophage infiltrates. Several studies reported amyloid deposition in most patients with DLB, 1,2,13 and there are clinical and neuropathological evidences to affirm that there were amyloid plaques in this brain before immunization: the patient had clinical features of AD, and the biochemical stage of tau pathological features was 9c, which correlated with a huge and widespread A␤ burden. 11 At least, we suggest that clusters of tau-positive neurites may correspond to senile plaques cleared out of the amyloid core ("ghost plaques").
Our patient had indisputable DLB since there was an extensive cortical monoaggregration and dimers aggregation of ␣-synuclein. A lower Braak stage is consistent with DLB associated with AD pathological features. 1 Lewy bodies were observed in the amygdala of 1 immunized patient, 7 but this finding is not restricted to DLB and is reported in AD. loid plaque burden, which was present to a lesser extent in some other cortical areas. A complete absence of extracellular amyloid deposits was described in 1 patient only in the frontal cortex. 8 In our case, the use of immunization against A␤ 42 peptides with AN-1792(QS-21) resulted in the total absence of amyloid aggregate in the whole brain, possibly because (1) our patient had the highest level of immune response after only 2 injections of AN-1792 (QS-21); (2) autopsy was performed 3 years after immunization (2 years later than the previous cases), leaving more time for the plaques' clearance. The absence of CD68-positive cells in this case, contrary to the others, might indicate the achievement of an earlier A␤ phagocytosis; and (3) amyloid plaques may be more of the diffuse type and less numerous in DLB than in AD [16] [17] [18] ; thus, the clearance may be facilitated. The A␤ 42 plaque density is more important in patients with DLB than in patients with AD, whereas the A␤ 40 density is lower in patients with DLB. 13 However, it may be that antibodies generated after immunization with A␤ 42 are primarily N-terminal specific. 19 Focal inflammatory infiltrates of T lymphocytes in the meninges and the cerebrum, reported in the 2 cases with encephalitis, 6, 7 are not necessarily associated with the antibody response to immunization. 20 We did not observe such cells in our case. The patient did not have clinical evidence of encephalitis; however, autopsy was performed 3 years after immunization, a delay that could be sufficient to clear inflammatory cells.
This case suggests that A␤ immunization resulted in a significant clearance of amyloid deposits with remaining tau and synuclein pathological features in a brain with Lewy body variant AD. Despite the concomitant digestive disease that caused the patient's death, the functional and cognitive expression of the underlying degenerative brain disease remained globally stable during the 3 years after immunization. Thus, patients with a Lewy body variant should not be excluded from enrollment in A␤-immunization trials. 
